Weight Regain After Obesity Drug Treatment
Weight Regain After Stopping Anti-Obesity Medications: A Thorough Analysis
Table of Contents
New research highlights a meaningful trend of weight regain among individuals who stop taking anti-obesity medications (AOMs), even after experiencing ample weight loss during treatment. A meta-analysis of 11 randomized trials, involving over 2,400 participants, reveals that weight regain can begin as early as eight weeks after discontinuing medication and continue for an average of 20 weeks before stabilizing.
Understanding Anti-Obesity medications and Weight Management
The US Food and Drug Administration (FDA) has approved six anti-obesity medications to aid in weight loss. These include well-known drugs like orlistat, phentermine-topiramate, and semaglutide. Additionally, glucagon-like peptide-1 (GLP-1) therapies, initially developed for diabetes management, have increasingly been prescribed for weight loss due to their efficacy. Though, emerging studies suggest that the benefits of these medications may not be permanent, with patients frequently enough regaining lost weight after cessation.
Key Medications Studied
The meta-analysis, led by Xiaoling Cai and Linong Ji, examined data from studies focusing on various AOMs:
GLP-1 Receptor Agonists (RAs): Six studies specifically investigated GLP-1 RAs.
GLP-1 and GLP Dual RAs: One study focused on this combined class.
Orlistat: One study examined the effects of orlistat.
Phentermine-Topiramate: Two studies analyzed this combination therapy.
Naltrexone-Bupropion: One study included this medication.
The analysis encompassed data from 1,574 participants in treatment groups and 893 in control groups, measuring weight change through alterations in body weight and Body Mass Index (BMI) post-medication.
The Trajectory of Weight Regain
The comprehensive meta-analysis revealed a consistent pattern of weight regain following the discontinuation of AOMs.
Post-Discontinuation Weight Changes
The study found that while AOMs were effective in promoting significant weight loss during treatment, a noticeable trend of weight regain commenced approximately eight weeks after stopping the medication. This regain continued for an average of 20 weeks, after which weight typically plateaued. Participants experienced significant weight regain at multiple follow-up points: eight, 12, and 20 weeks after discontinuing their AOMs.
Factors Influencing Weight Regain
The extent of weight regain was not uniform and was influenced by several critical factors:
Medication Type: Different AOMs were associated with varying degrees of weight regain.
Presence of Diabetes: The study controlled for whether participants had diabetes, acknowledging its potential impact on metabolic responses.
Lifestyle changes: The consistency and adherence to lifestyle modifications, such as diet and exercise, played a crucial role. For instance, participants who completed a 36-week treatment with tirzepatide, a GLP-1 RA, regained nearly half of their lost weight after transitioning to a placebo.
Limitations and Broader Context
The authors acknowledge certain limitations in their meta-analysis.The study did not include data from lifestyle interventions or bariatric surgery, which limits direct comparisons between different weight loss approaches. Furthermore, the researchers note that weight regain is a phenomenon observed with other weight loss methods, including surgical interventions like gastric bypass and vertical banded gastroplasty, suggesting that maintaining weight loss long-term remains a complex challenge across various strategies.
Source: Wu, H., et al. (2025).Trajectory of the body weight after drug discontinuation in the treatment of anti-obesity medications. BMC Medicine. doi.org/10.1186/s12916-025-04200-0.